Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor vs Clopidogrel in PCI (CHAMPION PHOENIX)
NCT01156571Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Sep 2010
- Primary completion
- Dec 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of cangrelor in acute coronary syndrome (ACS), coronary artery disease (CAD), stable angina, ST-segment elevation myocardial infarction (STEMI), non–ST-segment elevation acute coronary syndrome (NSTE-ACS), sponsored by The Medicines Company. Started Sep 2010; status: completed.
02
Drugs
cangrelor
03
Conditions
acute coronary syndrome (ACS)coronary artery disease (CAD)stable anginaST-segment elevation myocardial infarction (STEMI)non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT01156571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156571.